IKZF1/IKZF3 Degrader Development: Molecular Glue Design and CRBN Recruitment

* Please be kindly noted that our services and products are intended for research use by organizations or companies and are not intended for individual use.

Consult with Our Experts

What Are IKZF1 and IKZF3, and Which Family Members Are Suitable for Degrader Development?

IKZF1 (Ikaros) and IKZF3 (Aiolos) are members of the Ikaros family of C₂H₂ zinc-finger transcription factors. They regulate transcription through DNA recognition, chromatin-associated complexes, and homo- or heterodimerization with related IKZF proteins. Their architecture is important for degradation: the N-terminal zinc fingers support DNA binding, while the C-terminal zinc fingers participate in dimerization. ZF2 also contains the structural degron recognized by CRBN-bound molecular glues.

The best-established degradation route is not a conventional heterobifunctional PROTAC. Instead, thalidomide-derived molecular glues bind cereblon (CRBN), remodel its substrate-recognition surface, and recruit the ZF2 β-hairpin of IKZF1 or IKZF3 to the CRL4^CRBN ubiquitin ligase. A conserved glycine-containing loop is essential for fitting onto the drug-CRBN surface. IKZF1 Gln146 and the equivalent IKZF3 Gln147 further support recognition of amino-substituted glues through a water-mediated interaction. Closely related IKZF2 and IKZF4 carry histidine at the corresponding position and are therefore less compatible with classical lenalidomide- or pomalidomide-like interfaces, although next-generation molecular glues can overcome this sequence difference.

Degrader feasibility should therefore be defined by degron integrity rather than family name alone. Full-length IKZF1 and IKZF3, and isoforms that retain an intact ZF2 degron, are suitable starting points for CRBN molecular-glue programs. In contrast, splice variants or mutations that remove or distort the relevant zinc finger can reduce recruitment. Research has also shown that substitutions around the degron, including the glutamine and adjacent glycine-loop residues, can change degradation sensitivity. These sequence features should be mapped before compound design because structural changes can also alter degrader recognition.

Table 1. IKZF Family Features Relevant to Degrader Design.

What Have Developed IKZF1/IKZF3 Molecular Glues Revealed About Degrader Design?

The progression from thalidomide to lenalidomide and pomalidomide, and then to structurally extended CRBN modulators such as iberdomide and mezigdomide, shows that IKZF1/IKZF3 degradation is controlled by more than binary CRBN affinity. The compound must fit the CRBN tri-tryptophan pocket, present a compatible IKZF-facing surface, and stabilize a degradation-competent ternary assembly. Small changes around the solvent-exposed ring can shift which zinc-finger proteins are recruited, while larger extensions can increase CRBN engagement or control receptor conformation.

Table 2. Representative IKZF1/IKZF3 Molecular Glues and Design Lessons.

Three practical lessons emerge. First, binary affinity is not enough: a CRBN binder that occupies the pocket can still fail to degrade IKZF1/IKZF3 if its exposed surface clashes with the ZF2 degron. Second, the neosubstrate-facing surface is a tunable recognition element: ring substituents can preserve, weaken, or redirect zinc-finger recruitment. Third, advanced glues can work through receptor allostery: extending a compound toward additional CRBN surfaces can stabilize a productive conformation without requiring a classical linker to a separate target ligand.

Minimal Glutarimide-Based Molecular Glues for Dual IKZF1/IKZF3 Degradation

Recognition Site: The Conserved ZF2 Degron Shared by IKZF1 and IKZF3

The most validated recognition site is the ZF2 β-hairpin G-loop. The conserved glycine permits close packing against the CRBN-glue surface, while IKZF1 Gln146 and IKZF3 Gln147 provide a compound-facing side chain that distinguishes these proteins from related family members. Adjacent residues maintain the zinc-finger fold and control how the loop approaches CRBN. For a minimal-glue program, preserve this geometry as the primary design constraint and use degron mutants as mechanistic controls.

Warhead Chemistry: Glutarimide Anchor and Isoindole Ring Modification

The glutarimide group is the classical CRBN-binding anchor and occupies the conserved tri-tryptophan pocket. The opposite aromatic ring is comparatively exposed and participates in the induced interface. Lenalidomide and pomalidomide demonstrate the value of a C4 amino group, which can support a water-mediated interaction with the IKZF1/IKZF3 glutamine. Recommended optimization therefore starts from a validated glutarimide scaffold and varies the exposed ring cautiously, retaining the anchor geometry while measuring both CRBN occupancy and IKZF degradation.

Exit-Vector Design: Substitution Patterns That Replace a Classical Linker

Minimal molecular glues do not contain a PROTAC linker. Their "exit vector" is the direction in which a ring substituent projects from the CRBN-bound core toward the neosubstrate interface. C4, C5, and C6 changes can alter the local fit around CRBN His353 and IKZF1 Gln146. Bulky substitution can abolish IKZF recruitment even when CRBN binding remains strong. A practical series should therefore compare small polar, small hydrophobic, and sterically expanded substituents while keeping the glutarimide anchor constant.

E3 Recruitment: CRBN Engagement and CRL4^CRBN Complex Assembly

Productive degradation requires more than isolated CRBN binding. The glue-bound receptor must recruit IKZF1/IKZF3 in a geometry that permits ubiquitin transfer by the assembled CRL4^CRBN machinery. Confirm CRBN dependence with competition or genetic controls, then connect ternary-complex formation to ubiquitination and protein depletion. When two analogues have similar CRBN occupancy but different degradation, prioritize interface geometry and cooperativity rather than simply increasing binary ligand affinity.

Table 3. Minimal Glutarimide-Based IKZF1/IKZF3 Molecular Glue Design Summary.

Extended CRBN Molecular Glues for Deeper IKZF1/IKZF3 Degradation

Recognition Site: Interface Extension Beyond the β-Hairpin Glycine Loop

Extended CRBN molecular glues should not be assumed to make many new direct contacts with IKZF1. High-resolution structures of mezigdomide still show the canonical ZF2 glycine loop as the central neosubstrate contact. The major extension occurs on the CRBN side, where additional compound features engage receptor surfaces outside the minimal pocket. The design goal is therefore to preserve the ZF2-facing geometry while using distal groups to increase CRBN engagement, organize the receptor, and improve the lifetime of a productive ternary assembly.

Warhead Chemistry: High-Affinity, Conformationally Biased CRBN Binders

Iberdomide demonstrates one route: add hydrophobic functionality that improves CRBN engagement while retaining the glue surface required for IKZF recruitment. Mezigdomide goes further by adopting a folded, U-like architecture with distal aromatic and heterocyclic elements that engage additional CRBN surfaces. Recommended optimization should compare affinity, cellular occupancy, conformational bias, and IKZF1/IKZF3 degradation together. A higher-affinity CRBN ligand is useful only if the complete surface remains compatible with the desired neosubstrate.

Linker Design: Spacers Linking the Glutarimide to Neosubstrate Contact Groups

In this molecular-glue context, "linker" means an internal spacer or bridging element, not a classical PROTAC linker joining two independent ligands. Aryl, piperidine, piperazine, and related rigid units can position distal substituents toward CRBN surface pockets or shape the exposed glue face. Start with short, conformationally restricted bridges and compare them with more flexible analogues. Excess flexibility may reduce the population of productive conformations, while excessive rigidity can create steric clashes with CRBN or the ZF2 degron.

E3 Recruitment: Stabilizing the Closed, Degradation-Competent CRBN State

CRBN can adopt open and closed conformations, and structural work shows that ligand binding can promote the closed state required for stable Ikaros recruitment. Mezigdomide extends toward the CRBN Lon domain and helps stabilize this closed architecture. This suggests a useful optimization axis beyond affinity: design compounds that favor productive receptor conformation. Test conformationally biased analogues with ternary-complex assays, ubiquitination measurements, and degradation kinetics to determine whether stronger closure translates into faster or deeper IKZF1/IKZF3 depletion.

Table 4. Extended Molecular Glue Design Summary.

CRBN Scaffold Diversification Beyond Classical Glutarimide-Based Scaffolds

Recognition Site: Preserving ZF2 Recognition While Changing the CRBN Anchor

Replacing the classical scaffold is possible, but the design tolerance is narrow if IKZF1/IKZF3 degradation must be preserved. The ZF2 loop still has to approach the glue-bound CRBN surface with the correct orientation. Alternative binders that maintain strong CRBN affinity can lose IKZF degradation because their ring shape or substituents occupy the neosubstrate interface differently. Use IKZF1 ZF2 ternary structures as a steric filter and reject designs that occlude the glycine loop.

Warhead Chemistry: Ring-Modified Isoindoles, Fused Heterocycles, and Glutarimide Surrogates

Research on phenyl-substituted isoindolinones, benzimidazole-type CRBN ligands, and achiral dihydrouracil-based recruiters shows that CRBN binding can be separated from classical IKZF molecular-glue behavior. Several such ligands retain CRBN engagement yet do not degrade IKZF1/IKZF3, making them valuable negative-design precedents. For an IKZF-directed glue, diversify the exposed ring first and treat radical anchor replacement as a second-stage strategy that must be revalidated for CRBN binding, induced IKZF recruitment, and ubiquitination.

Linker Design: Rigid Bridging Units That Rebuild a Productive Interface Geometry

Scaffold-diversified glues may require short rigid bridges to reproduce the spatial relationship normally created by the classical glutarimide–isoindole architecture. The bridge should restore the correct distance between the CRBN anchor and the neosubstrate-facing surface without introducing excessive rotatable bonds. Heteroaromatic rings, fused units, or constrained amines can be used to tune projection angles. Because these compounds remain molecular glues, the bridge is an intramolecular geometry element rather than a linker connecting a separate IKZF ligand.

E3 Recruitment: Distinct CRBN Binding Footprints and Reduced Scaffold Overlap

A new CRBN chemotype can occupy a different set of receptor contacts and change the induced protein surface. That can be useful for avoiding unwanted neosubstrates, but it can also eliminate IKZF1/IKZF3 recruitment. Measure CRBN occupancy and neosubstrate degradation independently. If a new scaffold binds CRBN strongly but fails to recruit IKZF1/IKZF3, treat it as a potential E3 recruiter for bivalent degraders rather than forcing it into an IKZF molecular-glue program.

Table 5. CRBN Scaffold Diversification Strategy.

Selectivity-First Glue Design Against the Wider Zinc Finger Degrome

Recognition Site: Gln146/Gln147 Versus His141 Discrimination Across IKZF Members

IKZF1 Gln146 and IKZF3 Gln147 are central to the classical pomalidomide/lenalidomide interface, whereas IKZF2 contains His141 at the corresponding position. Converting the glutamine to histidine can strongly reduce classical glue responsiveness, while next-generation compounds can partially overcome this difference. This single-residue contrast is a powerful design handle: use IKZF1, IKZF3, and IKZF2 side-by-side to determine whether a new analogue preserves dual IKZF1/3 selectivity or broadens into other Ikaros-family proteins.

Warhead Chemistry: Sculpting the Drug Surface for Single-Residue Selectivity

Zinc-finger selectivity is controlled by the shape and chemistry of the drug-exposed surface, not simply by CRBN affinity. Pomalidomide favors a glutamine-compatible interface, whereas iberdomide-like extensions can recruit zinc fingers that classical glutarimide-based CRBN glues do not efficiently degrade. Design compact substituent matrices around positions facing the degron and compare polar, hydrophobic, and sterically demanding groups. The objective is to maximize the desired IKZF1/IKZF3 interaction energy while creating unfavorable contacts for competing zinc-finger degrons.

Exit-Vector Design: Orienting Substituents Away From CK1α and GSPT1 Recruitment

CK1α and GSPT1 provide two important off-target benchmarks because they use CRBN-induced β-hairpin recognition but respond to different chemical surfaces. Lenalidomide can efficiently recruit CK1α, whereas more extended CRBN ligands can acquire GSPT1 activity. Avoid assuming that an IKZF-potent analogue is selective. Use structure-guided exit-vector placement, then profile IKZF1, IKZF3, CK1α, GSPT1, and representative zinc-finger proteins in the same concentration and time window. Proteomic confirmation is preferred once a lead series emerges.

E3 Recruitment: CRBN Dependence Versus Switching to Alternative Ligases

For a true IKZF molecular glue, CRBN remains the most validated ligase receptor because the ZF2 degron has evolved into a well-characterized induced interface with CRBN-bound glues. Switching to another E3 is not a simple ligand substitution; it creates a new molecular-glue discovery problem. Alternative ligases are more practical for bivalent degraders where an independent IKZF binder is available. Within glue programs, first optimize CRBN surface selectivity and confirm CRBN-dependent ubiquitination before considering a different ligase system.

Table 6. Selectivity-First IKZF1/IKZF3 Glue Design Summary.

Bivalent Degrader Development Directly Targeting IKZF1/IKZF3 Zinc Finger Arrays

Direct bivalent degradation of IKZF1/IKZF3 is much less established than CRBN molecular-glue degradation. No broadly validated small-molecule IKZF1/IKZF3 warhead has emerged as a standard equivalent to kinase inhibitors used in conventional PROTAC design. Accordingly, this route should be treated as an exploratory strategy rather than a mature benchmark. Its main value is mechanistic: an independent IKZF-binding ligand could, in principle, enable degradation through VHL or a non-glue CRBN recruiter and could address variants that no longer present the canonical ZF2 molecular-glue degron.

Recognition Site: DNA-Binding Zinc Finger Arrays and Dimerization Interfaces

Potential direct-binding regions include the N-terminal DNA-binding zinc-finger array and the C-terminal dimerization zinc fingers. ZF2/ZF3 are structurally defined but present relatively shallow protein/DNA recognition surfaces rather than deep pockets. The C-terminal dimerization region offers a protein-protein interface but is similarly challenging for small molecules. Site selection should therefore start with ligandability mapping, fragment or peptide screening, and structural confirmation before a degrader campaign is launched.

Warhead Selection: Small-Molecule and Peptide Binders for IKZF Surfaces

Because validated direct IKZF1/IKZF3 small-molecule ligands are limited, warhead discovery is the rate-limiting step. Candidate binders can arise from fragment screening, DNA-interface mimetics, constrained peptides, or protein-interaction ligands. The selected binder must retain affinity after functionalization at a solvent-exposed position. Measure binding before and after installing a linker handle so degradation failure can be separated from loss of target engagement.

Linker Design: Length, Rigidity, and Attachment Position on the CRBN Ligand

Once a direct IKZF binder is available, the linker should be optimized as a conventional PROTAC element. Build a focused matrix that varies attachment site, short-to-intermediate length, polarity, and conformational restriction. If CRBN is used, the recruiter choice matters greatly: classical glutarimide-based CRBN ligands can independently induce IKZF1/IKZF3 degradation and therefore confound proof of a warhead-driven mechanism. Non-glue CRBN chemotypes or orthogonal ligases are preferable when the objective is to demonstrate direct bivalent targeting.

E3 Ligase Selection: CRBN Ligands Versus VHL and Alternative Recruiters

VHL provides a useful orthogonal comparator because it avoids the native CRBN molecular-glue mechanism for IKZF1/IKZF3. CRBN can still be used when a non-glue recruiter has been validated not to deplete IKZF proteins on its own. Recent non-classical CRBN ligands, including dihydrouracil-based recruiters designed to minimize degradation of classical CRBN neosubstrates, illustrate this strategy. In every case, include recruiter-only and warhead-only controls so that direct PROTAC activity is distinguished from intrinsic molecular-glue effects.

Table 7. Exploratory Bivalent IKZF1/IKZF3 Degrader Design Strategy.

Why Do IKZF1/IKZF3 Degrader Programs Fail, and How Can Each Failure Mode Be Optimized?

Weak or Non-Productive Ternary Complex Formation

Strong CRBN binding does not guarantee IKZF degradation. A compound may occupy CRBN but present the wrong surface to ZF2, reduce cooperativity, or orient the neosubstrate poorly for ubiquitination. Compare binary CRBN occupancy with direct ternary-complex measurements and degradation. For molecular glues, adjust ring substituents, distal CRBN contacts, or conformational bias. For bivalent degraders, vary warhead exit vector, linker length, and E3 recruiter independently rather than changing all three at once.

Permeability, Stability, and Exposure Shortfalls That Limit Cellular Depletion

Minimal molecular glues are compact, but extended CRBN-binding structures and bivalent degraders can accumulate polarity, aromatic surface, and conformational complexity. A compound that performs well in a biochemical ternary-complex assay may still fail in cells. Measure solubility, chemical stability, permeability, intracellular exposure, and target degradation in parallel. When potency drops after structural extension, distinguish cellular-access problems from ternary-complex defects before increasing CRBN affinity.

Off-Target Neosubstrate Degradation Outside the IKZF1/IKZF3 Window

The CRBN zinc-finger degrome is broader than IKZF1/IKZF3. Small changes to the glue surface can recruit IKZF2, SALL-family zinc fingers, ZFP91, CK1α, GSPT1, or other proteins. Early selectivity panels should therefore accompany potency optimization. When an analogue gains an unwanted target, map which substituent faces the competing degron and design matched analogues that reduce that interaction. Quantitative proteomics is especially useful for distinguishing a clean dual-IKZF profile from a broad CRBN-neosubstrate signature.

Degradation Escape Driven by CRBN Alterations and Compensatory Signaling

Loss or reduction of functional CRBN, changes in the CRBN drug-binding region, disruption of other CRL4 components, or mutations within the IKZF degron can all reduce glue-driven degradation. In research models, lower CRBN abundance correlates with weaker IKZF depletion, while stronger next-generation CRBN molecular glue binders can sometimes retain activity when receptor levels are limiting. Downstream signaling can also buffer target loss. When degradation and phenotype diverge, measure CRBN, IKZF1/3, ubiquitination, and downstream transcriptional markers separately rather than assuming one resistance mechanism.

BOC Sciences Support for IKZF1/IKZF3 Degrader Development

BOC Sciences supports both CRBN molecular-glue programs and exploratory bivalent IKZF degrader projects. Our workflow can begin with target degradability assessment for TPD development, then progress through CRBN ligand design services, focused synthesis, and mechanism-based evaluation. For glue programs, we prioritize degron compatibility, CRBN surface engineering, and neosubstrate selectivity. For bivalent concepts, we separately optimize direct IKZF engagement, linker geometry, and E3 selection.

Table 8. Representative CRBN Ligand Reagents and Glue Building Blocks.

Target and Degron Feasibility Assessment Across IKZF Family Members

• Map ZF2 degron integrity in IKZF1, IKZF3, selected family comparators, variants, and engineered mutants
• Assess whether the project requires dual IKZF1/IKZF3 depletion or narrower family selectivity
• Define appropriate CRBN, degron-mutant, recruiter-only, and proteasome controls
• Prioritize molecular-glue versus bivalent strategies according to target-site accessibility and available binders

CRBN Ligand and Molecular Glue Scaffold Design

• Design classical glutarimide-based, extended CRBN-binding, and scaffold-diversified molecular glue series
• Use molecular glue technology development to connect structural design with induced-proximity testing
• Optimize exposed-ring substitution, internal rigid bridges, and distal CRBN-contact groups
• Build matched analogues for potency, selectivity, and negative-control interpretation

Custom Synthesis of Glutarimide-Based Degrader Building Blocks and Linkers

• Prepare CRBN-binding cores, functionalized glutarimide-based CRBN ligand analogues, and click-compatible recruiter intermediates
• Develop short rigid, PEG, alkyl, aromatic, and heterocyclic linker matrices for bivalent degrader studies
• Use pomalidomide linker design services when CRBN attachment-site and linker geometry require focused optimization
• Provide purification and analytical characterization for screening-ready compound sets

Ternary Complex, Degradation, and Degradome Profiling Services

• Characterize induced complexes using PROTAC ternary complex assay approaches adapted to the degrader format
• Confirm polyubiquitination with protein ubiquitination services
• Quantify IKZF1 and IKZF3 depletion using degradation ability assay workflows with concentration and time-course analysis
• Extend prioritized compounds into focused neosubstrate panels or broader proteomic profiling

Explore featured products that can expand your research options and accelerate your next discovery.

Access end-to-end service solutions that help bring efficiency, flexibility, and expertise to your research pipeline.

News

• Discovery of Molecular Glue Degraders
• From Thalidomide to Pomalidomide: The Evolution of Cereblon Ligands in Drug Discovery
• Overcoming Off-Target Effects: Reducing Zinc Finger Protein Degradation in CRBN-Based PROTACs

Technical Information

• The Next Frontier of PROTACs: Development of Molecular Glues
• How Pomalidomide Enables Targeted Protein Degradation in Modern PROTAC Design?
• Degrader Building Blocks for Targeted Protein Degradation